Justified and unjustified use of growth hormone

Postgraduate Medical Journal

Volumn 80, Issue 948, 2004, Pages 577-580

  Van Der Lely, A J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ESTROGEN; GLUCOCORTICOID; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; LIPID; PLACEBO; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

BODY COMPOSITION; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HEART FAILURE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS DISEASE; LEAN BODY WEIGHT; LONGEVITY; MORBID OBESITY; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; OSTEOPOROSIS; OUTCOMES RESEARCH; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SHORT STATURE;

ADULT; CHILD; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; UNNECESSARY PROCEDURES;

EID: 6344285680     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2003.017467     Document Type: Review

References (56)

1. Fine RN, Sullivan EK, Tejani A. The impact of recombinant human growth hormone treatment on final adult height. Pediatr Nephrol 2000;14:679-81.
2. Frindik JP, Baptista J. Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study. Pediatrics 1999;104:1000-4.
3. Johannsson G, Bengtsson BA, Ahlmen J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999;33:709-17.
4. Janssen F, Damme-Lombaerts R, Van Dyck M, et al. Impact of growth hormone treatment on a Belgian population of short children with renal allografts. Pediatr Transplant 1997;1:190-6.
5. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with Turner's syndrome treated with once or twice daily growtn hormone injections. Dutch Advisory Group on Growth Hormone. Arch Dis Child 1999;80:36-41.
6. Ramaswami U, Hindmarsh PC, Brook CG. Growth hormone therapy in hypochondroplasia. Acta Paediatr 1999;88(suppl):116-17.
7. Simon D, Touati G, Prieur AM, et al. Growth hormone treatment of short stature and metabolic dysfunction in juvenile chronic arthiritis. Acta Paediatr Suppl 1999;88:100-5.
8. Deijen JB, van der Veen EA. The influence of growth hormone (GH) deficiency and GH replacement on quality of life in GH-deficient patients. J Endocrinol Invest 1999;22:127-36.
9. Abs R, Bengtsson B, Hernberg S, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 1999;50:703-13.
10. Svensson J, Johannsson G, Bengtsson BA. Body composition and quality of life as markers of the efficacy of growth hormone replacement therapy in adults. Horm Res 2001;55(suppl 2):55-60.
11. Johannsson G, Svensson J, Bengtsson BA. Growth hormone and ageing. Growth Horm IGF Res 2000;10(suppl B):S25-30.
12. Bengtsson BA, Abs R, Bennmarker H, et al. The effects of treatment and the individual respansiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 1999;84:3929-35.
13. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-8.
14. Kehely A, Bates PC, Frewer P, et al. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab 2002;87:1974-9.
15. Herschbach P, Henrich G, Strasburger G, et al. Development and psychometric properties of a disease-specific quality of life questionnaire for adult patients wild growth hormone deficiency. Eur J Endocrinol 2001;145:255-65.
16. Colao A, Di Somma C, Pivonello R, et al. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 2002;87:1088-93.
17. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785-92.
18. Kissmeyer-Nielsen P, Jensen MB, Laurberg S. Perioperative growth hormone treatment and functional outcome after major abdominal surgery: a randomized, double-blind, controlled study. Ann Surg 1999;229:298-302.
19. Barry MC, Mealy K, Sheehan SJ, et al. The effects of recombinant human growth hormone on cardiopulmonary function in elective abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 1998;16:311-19.
20. van der Lely AJ, Lomberts SW, Jauch KW, et al. Use of human GH in elderly patients with accidental hip fracture. Eur J Endocrinol 2000;143:585-92.
21. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996;125:873-82.
22. Frisch H. Growth hormone and body composition in athletes. J Endocrinol Invest 1999;22:106-9.
23. Hulthen L, Bengtsson BA, Sunnerhagen KS, et al. GH is needed for the maturation of muscle mass and strength in adolescents. J Clin Endocrinol Metab 2001;86:4765-70.
24. Janssen YJ, Doornbos J, Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999;84:279-84.
25. Jargensen JO, Vahl N, Hansen TB, et al. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin Endocrinol (Oxf) 1996;45:681-8.
26. Macintyre JG. Growth hormone and athletes. Sports Med 1987,4:129-42.
27. Bowers LD. Abuse of performance-enhancing drugs in spart. Ther Drug Monit 2002;24:178-81.
28. Congeni J, Miller S. Supplements and drugs used to enhance athletic performance. Pediatr Clin North Am 2002;49:435-61.
29. Wu Z, Bidlingmaier M, Dall R, et al. Detection of doping with human growth hormone. Lancet 1999;353:895.
30. Armanini D, Faggian D, Scaroni C, et al. Growth hormone and insulin-like growth factor I in a Sydney Olympic gold medallist. Br J Sports Med 2002;36:148-9.
31. Coschigano KT, Clemmons D, Bellush LL, et al. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 2000;141:2608-13.
32. Bartke A, Coschigano K, Kopchick J, et al. Genes that prolong life: relationships of growth hormone and growth to aging and life span. J Gerontol A Biol Sci Med Sci 2001;56:B340-9.
33. Carter CS, Ramsey MM, Ingram RL, et al. Models of growth hormone and IGF-1 deficiency: applications to studies of aging processes and life-span determination. J Gerontol A Biol Sci Med Sci 2002;57:B177-88.
34. Rose MR. Can human aging be postponed? Sci Am 1999;281:106-11.
35. Kalu DN, Orhii PB, Chen C, et al. Aged-rodent models of long-term growth hormone therapy: lack of deleterious effect on longevity. J Gerontol A Biol Sci Med Sci 1998;53:B452-63.
36. Samaras TT, Elrick H, Storms LH. Height, health and growth hormone. Acta Paediatr 1999;88:602-9.
37. Frederiksen H, McGue M, Jeune B, et al. Do children of long-lived parents age more successfully? Epidemiology 2002;13:334-9.
38. Taira K, Tanaka H, Arakawa M, et al. Sleep health and lifestyle of elderly people in Ogimi, a village of longevity. Psychiatry Clin Neurosci 2002;56:243-4.
39. Barzilai N, Shuldiner AR. Searching for human longevity genes: the future history of gerontology in the past-genomic era. J Gerontol A Biol Sci Med Sci 2001;56:M83-7.
40. Cassel CK. Successful aging. How increased life expectancy and medical advances are changing geriatric care. Geriatrics 2001;56:35-9.
41. Promislow DE. On size and survival: progress and pitfalls in the allometry of life span. J Gerontol 1993;48:B115-23.
42. Samaras TT, Storms LH. Impact of height and weight on life span. Bull World Health Organ 1992;70:259-67.
43. Johansson S. Longevity in women. Cardiovasc Clin 1989;19:3-16.
44. Simopoulos AP, Van Itallie TB. Body weight, health, and longevity. Ann Intern Med 1984;100:285-95.
45. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
46. Cuttica CM, Castoldi L, Gorrini GP, et al. Effects of six-month administration of recombinant human growth hormone to healthy elderly subjects. Aging (Milano) 1997;9:193-7.
47. Lange KH, Isaksson F, Juul A, et al. Growth hormone enhances effects of endurance training on oxidative muscle metabolism in elderly women. Am J Physiol Endocrinol Metab 2000;279:E989-96.
48. Butterfield GE, Thompson J, Rennie MJ, et al. Effect of rhGH and rhIGF-1 treatment on protein utilization in elderly women. Am J Physiol 1997;272:E94-9.
49. Janssens H, Vanderschueren DM. Endocrinological aspects of aging in men: is hormone replacement of benefit? Eur J Obstet Gynecol Reprod Biol 2000;92:7-12.
50. Savine R, Sonksen PH. Is the somatopause an indication for growth hormone replacement? J Endocrinol Invest 1999;22:142-9.
51. von Werder K. The somatopause is no indication for growth hormone therapy. J Endocrinol Invest 1999;22:137-41.
52. Chipman JJ, Attanasio AF, Birkett MA, et al. The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf) 1997;46:473-81.
53. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
54. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
55. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
56. Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002;360:273-7.